Market Cap
AU$316.0m
Last Updated
2021/05/13 08:07 UTC
Data Sources
Company Financials +
Executive Summary
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Immutep's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMM is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IMM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
Market Performance
7 Day Return
5.8%
IMM
-1.5%
AU Biotechs
-0.7%
AU Market
1 Year Return
203.3%
IMM
-10.9%
AU Biotechs
35.4%
AU Market
Return vs Industry: IMM exceeded the Australian Biotechs industry which returned -10.9% over the past year.
Return vs Market: IMM exceeded the Australian Market which returned 35.4% over the past year.
Shareholder returns
| IMM | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.8% | -1.5% | -0.7% |
| 30 Day | 1.1% | 2.3% | 0.8% |
| 90 Day | 9.6% | -1.6% | 2.5% |
| 1 Year | 203.3%203.3% | -10.0%-10.9% | 39.6%35.4% |
| 3 Year | 69.7%68.5% | 59.5%54.3% | 30.2%14.8% |
| 5 Year | 1.8%1.1% | 148.2%133.8% | 61.7%31.7% |
Long-Term Price Volatility Vs. Market
How volatile is Immutep's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Immutep Limited (ASX:IMM) Popular Amongst Institutions?1 month ago | Simply Wall St
Is Immutep's (ASX:IMM) 200% Share Price Increase Well Justified?3 months ago | Simply Wall St
How Is Immutep's (ASX:IMM) CEO Compensated?Valuation
Is Immutep undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IMM (A$0.46) is trading below our estimate of fair value (A$19.62)
Significantly Below Fair Value: IMM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IMM is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: IMM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMM's PB Ratio (4.9x) is in line with the AU Biotechs industry average.
Future Growth
How is Immutep forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
82.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: IMM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMM's is expected to become profitable in the next 3 years.
Revenue vs Market: IMM is forecast to have no revenue next year.
High Growth Revenue: IMM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMM is forecast to be unprofitable in 3 years.
Past Performance
How has Immutep performed over the past 5 years?
30.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMM is currently unprofitable.
Growing Profit Margin: IMM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMM is unprofitable, but has reduced losses over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: IMM has a negative Return on Equity (-45.08%), as it is currently unprofitable.
Financial Health
How is Immutep's financial position?
Financial Position Analysis
Short Term Liabilities: IMM's short term assets (A$62.3M) exceed its short term liabilities (A$5.2M).
Long Term Liabilities: IMM's short term assets (A$62.3M) exceed its long term liabilities (A$10.6M).
Debt to Equity History and Analysis
Debt Level: IMM's debt to equity ratio (15.6%) is considered satisfactory.
Reducing Debt: IMM's debt to equity ratio has increased from 11.6% to 15.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IMM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Immutep current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Marc Voigt (47 yo)
6.83yrs
Tenure
AU$926,248
Compensation
Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD716.97K) is above average for companies of similar size in the Australian market ($USD512.47K).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: IMM's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: IMM's board of directors are considered experienced (3.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.9%.
Top Shareholders
Company Information
Immutep Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Immutep Limited
- Ticker: IMM
- Exchange: ASX
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$316.009m
- Shares outstanding: 672.36m
- Website: https://www.immutep.com
Number of Employees
Location
- Immutep Limited
- 95 Pitt Street
- Level 12
- Sydney
- New South Wales
- 2000
- Australia
Listings
Biography
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/13 08:07 |
| End of Day Share Price | 2021/05/13 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.